Faculty Honors & Achievements
- Dr. Hiranmoy Das was invited to talk at the 1st International Conference on Clinical Trials and Innovative Therapies at Cape Town, South Africa on July 24-26, 2017. He was also invited to serve on several NIH study section meetings in 2017.
- Dr. Abraham Al-Ahmad has been accepted for participation in the Early Career Reviewer (ECR) Program at the Center for Scientific Review (CSR), National Institutes of Health
- Dr. Constantinos Mikelis was invited for a talk at the 14th Annual International Innate Immunity Conference on June 19-24, 2017 at Heraklion, Crete.
- Dr. Luca Cucullo and Dr. Thomas Abbruscato have received a Multi-PI NIH R01 Grant in the amount of $1.9 million.
- Dr. Richard Leff received a $2.5 million grant from CPRIT to fund the North Texas Pharmacology Cancer Core in Dallas, TX.
- Dr. Kalkunte Srivenugopal received a $1.2 million CPRIT Grant.
- Dr. Laurence Wood received a R15 grant from NIH.
New Grants and Awards
- Dr. Fakhrul Ahsan received CMREF grant
- Dr. Abraham Al-Ahmad received GLUT1 Deficiency Foundation grant
- Dr. Magdalena Karbowniczek received a Women's Health Seed Grant from Laura W. Bush Institute for Women's Health
- Dr. Maciej Markiewski received a Women's Health Seed Grant from Laura W. Bush Institute for Women's Health
High Impact Publications
Dr. Sanjay K. Srivastava, Professor of Biomedical Sciences and Associate Dean for Office of Sciences, and his team's recent publication, "Penfloridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis." Cancer Research, 76, 877-890, 2016. (Impact Factor 9.329) PMID: 26627008
Metastasis of breast cancer, especially to the brain, is the major cause of mortality. The inability of anticancer agents to cross the blood-brain-barrier represents a critical challenge for successful treatment. In the current study, Dr. Srivastava and his team investigated the antimetastatic potential of penfluridol, an antipsychotic drug frequently prescribed for schizophrenia with anticancer activity. His group demonstrated that penfluridol induced apoptosis and reduced the survival of several metastatic triple-negative breast cancer (TNBC) cell lines and suppressed tumor growth in various models.
Dr. Magdalena Karbowniczek, Associate Professor in the Department of Immunotherapeutics and Biotechnology in Abilene, and her team’s recent publication, “Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex." Dr. Karbowniczek’s laboratory studies the cellular and molecular mechanisms behind a rare disease tuberous sclerosis complex (TSC), which is caused by the inactivating mutations in tumor suppressor genes TSC1 and TSC2. The manuscript is scheduled for publication this year in the cancer journal Oncogene. (Impact Factor 8.459)...